指南与共识乳腺癌

早期乳腺癌降阶梯与升阶梯治疗:2017年圣加仑国际早期乳腺癌原发治疗专家共识会议

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
指南 / 共识 · Ann Oncol · 2017-01-01

2017年第15届圣加仑国际乳腺癌会议在奥地利维也纳召开,基于新证据评估早期乳腺癌局部与全身治疗的强度、疗程及副作用,按肿瘤分期与生物学特征升阶梯或降阶梯治疗。专家组就手术降阶梯、放疗升阶梯与降阶梯、基因表达签名指导化疗、辅助内分泌治疗升阶梯及双膦酸盐预防复发等给出推荐,并强调推荐需个体化调整。

要点

  • 导管原位癌可接受2 mm切缘;新辅助治疗后切除残留癌而非基线范围,多数患者可接受前哨淋巴结活检。
  • HER2阳性及三阴性II、III期乳腺癌优先选择新辅助治疗;高危患者区域淋巴结放疗升阶梯,低危患者鼓励省略瘤床加量。
  • ER阳性乳腺癌可借助基因表达签名避免化疗;高危绝经前女性辅助内分泌治疗加卵巢抑制,绝经后女性延长治疗,低危患者可避免。

核心结论

  • 专家组基于肿瘤分期与生物学特征,对早期乳腺癌局部和全身治疗进行升阶梯或降阶梯推荐,强调推荐针对多数常见临床表现而非所有患者。
  • 个体化辅助治疗需结合肿瘤特征、患者合并症与偏好,并管理治疗费用与可及性限制,这些限制在发达与发展中世界均可能影响诊疗。

研究设计与样本

  • 2017年在奥地利维也纳召开的第15届圣加仑国际乳腺癌会议,专家组回顾早期乳腺癌局部区域与全身治疗的大量新证据,按治疗强度、疗程和副作用评估,并依据肿瘤分期和肿瘤生物学预测的获益进行升阶梯或降阶梯。

主要发现

  • 专家组支持可降低手术并发症的干预:导管原位癌接受2 mm切缘;新辅助治疗患者切除残留癌而非基线癌范围;多数患者新辅助治疗后接受前哨淋巴结活检;HER2阳性和三阴性II、III期乳腺癌优先选择新辅助治疗。
  • 专家组支持高危患者区域淋巴结放疗升阶梯,同时鼓励低危患者省略瘤床加量。
  • 专家组认可基因表达签名可帮助许多ER阳性乳腺癌患者避免化疗。
  • 对较高风险肿瘤,专家组将辅助内分泌治疗推荐升阶梯:绝经前女性加卵巢抑制,绝经后女性延长治疗;低危患者可避免这些治疗。
  • 专家组推荐绝经后女性使用双膦酸盐预防乳腺癌复发。

关键数值与推荐

  • 导管原位癌切缘接受2 mm。
  • 新辅助治疗后切除残留癌而非基线癌范围,多数患者可接受前哨淋巴结活检。
  • HER2阳性和三阴性II、III期乳腺癌优先选择新辅助治疗。
  • 高危患者区域淋巴结放疗升阶梯,低危患者鼓励省略瘤床加量。
  • 较高风险肿瘤辅助内分泌治疗升阶梯:绝经前女性加卵巢抑制,绝经后女性延长治疗;低危患者可避免;绝经后女性推荐双膦酸盐预防复发。

临床怎么用

  • 专家组推荐导管原位癌切缘可接受2 mm。
  • 专家组支持新辅助治疗后切除残留癌而非基线癌范围,多数患者可接受前哨淋巴结活检。
  • 专家组支持HER2阳性和三阴性II、III期乳腺癌优先选择新辅助治疗。
  • 专家组支持高危患者区域淋巴结放疗升阶梯,鼓励低危患者省略瘤床加量。
  • 专家组推荐较高风险肿瘤辅助内分泌治疗升阶梯(绝经前加卵巢抑制、绝经后延长治疗),低危患者可避免;推荐绝经后女性使用双膦酸盐预防复发;推荐需个体化调整。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017. PMID: 28838210. doi:10.1093/annonc/mdx308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。